---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-018465"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T04:41:47.907424+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Interpace Q1 revenue $10.3M (+4% YoY); income from ops $0.6M; record test volume +10%

## Summary
- Q1 net revenue $10.3M, up 4% YoY from $9.8M; test volume up 10% to record levels.
- Income from continuing ops $0.6M vs $0.4M prior year; operating income $0.9M vs $0.7M.
- Adjusted EBITDA $1.0M vs $1.2M prior year; gross margin 59% vs 61%.
- Cash collections $10.2M; cash balance $2.8M at Mar 31, 2024, down from $5.6M due to $3.1M debt paydown.
- Fifteenth consecutive quarter of YoY volume growth; CEO cites adoption of ThyGeNEXT, ThyraMIRv2, PancraGEN.

## SEC filing metadata
- accession: 0001493152-24-018465
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000149315224018465/0001493152-24-018465-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000149315224018465/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-018465
- JSON: https://secwatch.observer/filing/0001493152-24-018465.json
- Plain text: https://secwatch.observer/filing/0001493152-24-018465.txt

## Key facts
- Earnings Releases
  INTERPACE BIOSCIENCES, INC. reported first quarter ended March 31, 2024 results: revenue $10.3 million, net income $0.6 million.
  - Period: first quarter ended March 31, 2024
  - Revenue: $10.3 million
  - Net income: $0.6 million
  - Result: reported results
  source text: stated in such filing. --- EX-99.1 () --- EX-99.1 2 ex99-1.htm Exhibit 99.1 Interpace Biosciences Announces First Quarter 2024 Financial and Business Results ● Q1 Revenue of $10.3 million; a 4% increase year-over-year ● Q1 Test volume up 10% year over year to record levels PARSIPPANY, NJ, May 9, 2024 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (“Interpace” or
  evidence_url: https://www.sec.gov/Archives/edgar/data/1054102/000149315224018465/0001493152-24-018465-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.